Effect of HLA-B27 status and body mass index on the clinical response to infliximab in ankylosing spondylitis patients

Effect of HLA-B27 status and body mass index on the clinical response to infliximab in ankylosing spondylitis patients

Background: Tumor necrosis factor-alpha inhibitors (infliximab) have changed the therapeutic approach to ankylosing spondylitis (AS). Body mass index (BMI) and HLA-B27 status may affect the response to infliximab. Methods: One hundred and seventy AS patients with active disease were enrolled in the...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohammed Hadi Al-Osami, Ekhlas Khalid Hameed, Ali Mohammed Al-Hamadani
Format: Article
Language:English
Published: SAGE Publishing 2018-01-01
Series:Indian Journal of Rheumatology
Subjects:
Ankylosing spondylitis
body mass index
HLA-B27
infliximab
Online Access:http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2018;volume=13;issue=1;spage=33;epage=37;aulast=Al-Osami
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items